Sage Journals: Discover world-class research

Abstract

Background

Recent studies suggest that serum lipids are associated with pegylated interferon-alpha (PEG-IFN-α) treatment response in chronic hepatitis C patients. However, the role of serum lipids in influencing the outcome of HBV treatment is not well understood. This study aims to investigate the association of serum lipids with the response to interferon-alpha treatment for chronic hepatitis B (CHB) patients.

Methods

We dynamically measured 11 clinical serum lipid parameters of 119 hepatitis B e antigen (HBeAg)-positive CHB patients, including 53 patients who achieved sustained response (SR) and 66 patients who achieved non-response (NR) induced by PEG-IFN-α treatment for 48 weeks.

Results

The dynamic analysis showed that the baseline serum total cholesterol (TCHO) level was higher in the NR group than that in the SR group (P=0.004). Moreover, the correlation analysis demonstrated a significant positive correlation between TCHO and hepatitis B surface antigen (HBsAg) at baseline (P=0.009). In addition, CHB patients with high baseline TCHO levels exhibited higher HBV DNA, HBsAg, HBeAg and hepatitis B e antibody (HBeAb) levels during early treatment periods (weeks 0, 4, 12 and 24) than those with the low TCHO levels. Furthermore, the logistic regression analysis identified that baseline serum TCHO was a risk factor for NR achievement (OR=4.94; P=0.047). Conclusions: Our results indicated that serum TCHO was associated with PEG-IFN-α therapeutic response in HBeAg-positive CHB patients which suggested that serum TCHO could be useful as an auxiliary clinical factor to predict poor efficacy of PEG-IFN-α therapy.

Introduction

More than 240 million people worldwide are chronically infected with HBV and HBV is a major cause of cirrhosis, which may lead to liver failure and liver cancer [1,2]. Thus far, interferons and nucleoside/ nucleotide analogues (NAs) are widely used to treat HBV [3]. Among them, pegylated interferon-alfa (PEG-IFN-α) possesses the highest off-treatment sustained response (SR) rate and relatively low risk of post-treatment relapse after a 48-week course of treatment in chronic hepatitis B (CHB) patients [4,5]. Nevertheless, the effect of PEG-IFN-α on HBV is still rather poor. For instance, the clearance of hepatitis B surface antigen (HBsAg) occurs in only 3% to 11% of CHB patients treated with PEG-IFN-α [6–8]. The loss of hepatitis B e antigen (HBeAg) occurs in only 30% of CHB patients treated with PEG-IFN-α [9,10]. Moreover, the underlying reason for this treatment non-response (NR) in HBV patients remains unknown.

Increasing evidence has supported that chronic HBV infection can influence serum lipid metabolism [11–13]. For example, HBV infection induces the expression of genes involved in cholesterol synthesis and promotes cholesterol provision [14]. The hepatitis B virus X protein can inhibit the secretion of apolipoprotein B (APO-B) and accelerate fatty acid synthase [15,16]. Conversely, serum lipids also influence the HBV infection [17–19]. However, serum lipid indexes that reflect the therapeutic efficacy of HBV treatments have not been so reliable. Currently, it has been confirmed that serum lipids are correlated with treatment response to PEG-IFN-α in chronic hepatitis C patients [20,21]. The low-density lipoprotein cholesterol (LDL-C) is a predictive factor of early and sustained responses to PEG-IFN-α plus ribavirin combination therapy in patients infected with HCV [22]. Higher baseline serum LDL and cholesterol levels may be significant prognostic indicators for the outcome of HCV treatment with a combination of IFN and ribavirin [23,24]. However, whether serum lipids play any role in influencing the outcome of HBV treatment has not yet been explored.

In this study, we aim to explore the levels of serum lipids in HBeAg-positive CHB patients receiving PEG-IFN-α treatment to investigate the association of serum lipids with PEG-IFN-α treatment response.

Methods

Patient characteristics

A total of 119 HBeAg-positive CHB patients who had received anti-HBV treatment by PEG-IFN-α for 48 weeks were enrolled in this study. CHB patients provided written informed consent and this study was approved by the Ethics Committee of the First Affiliated Hospital of Fujian Medical University. The inclusion criteria were as follows: the presence of serum HBsAg for 6 or more months; an age greater than 16 years old; a previous lack of antiviral treatment. PEG-IFN-α was commenced when the HBV DNA level was more than 20,000 IU/ml and when either the alanine aminotransferase (ALT) level was greater than 2x the upper limit of normal (40 U/l) or biopsy showed significant fibrosis/cirrhosis. The exclusion criteria were a coinfection with HCV or HIV, a history of organ transplantation, decompensated liver cirrhosis and a concurrent use of immunomodulatory drugs or corticosteroids. Two treatment strategies were performed among the 119 CHB patients. 65 patients received PEG-IFN-α monotherapy and the other 54 patients received PEG-IFN-α add-on NA therapy for 48 weeks. PEG-IFN-α was administered by intramuscular injection (PEG-IFN-α2a, 180 μg/week or PEG-IFN-α2b, 100 μg/week) for 48 weeks and NAs were given orally at the regular clinical dose (tenofovir disoproxil fumarate [TDF], 300 mg/day or adefovir [ADV], 10 mg/day or entecavir [ETV], 0.5 mg/day). According to curative effects at 24 weeks post-treatment (week 72), the 119 HBeAg-positive CHB patients were divided into two groups: SR group and NR group. A total of 53 patients achieved SR while the other 66 patients had NR after receiving 48 weeks of PEG-IFN-α monotherapy or PEG-IFN-α add-on NA treatment. SR to treatment was defined according to the EASL guidelines [25] as HBeAg <1 S/CO, HBV DNA <500 IU/ml and ALT <40 U/l when followed-up at 24 weeks post-treatment (week 72) in both of the treatment groups. Patients were considered to have NR to therapy if they did not meet all of the criteria above.

Measurement of clinical indicators

The clinical serum lipid indicators that were measured for this study included TCHO, triglyceride (TG), high-density lipoprotein cholesterol (HDL-C), HDL-C/C (the ratio of HDL-C to TCHO), LDL-C, very low-density lipoprotein cholesterol (VLDL-C), apolipoprotein A1 (APO-A1), APO-B, APO-A1/B, lipoprotein α (LP[α]) and non-esterified fatty acid (NEFA). The serum samples for clinical indicator measurement were obtained from fresh whole blood collected in tube without anticoagulants. All of the clinical indicators were quantified in samples taken at baseline and during the treatment period and follow-up periods. Sampling was performed at weeks 0, 4, 12, 24, 36, 48, 60 and 72 (week 0, namely baseline, was the time point at which treatment began). HBV DNA was detected by quantitative real-time PCR method (Sansure Biotech Inc., Hunan, China) and Roche Lightcycler 480 (Roche Corporation, Basel, Switzerland) with a lower limit of detection <500 IU/ml. HBsAg, HBeAg, anti-HBe and anti-HBc were quantified using an automated chemiluminescent microparticle immunology analyser (Abbott I2000, Abbott Laboratories, Chicago, IL, USA). Serum ALT and lipids were detected using an automatic biochemical analyser ADVIA 2400 (Siemens, Munich, Germany).

Statistical analyses

Data were performed using the SPSS version 20 software (SPSS, IBM, Chicago, IL, USA) and expressed as percentages and mean ± standard deviation (sd) or standard error of the mean (sem). Statistical comparisons between two groups were performed using the two-tailed Student's t-test if quantitative variables were normal and homogeneous distribution or Mann-Whitney U test if not. The χ² test was used to examine the differences for categorical variables. Correlations between variables were tested by the Spearman correlation coefficient. Univariate and multivariate logistic regression analyses were applied to determine the risk factors of SR. Differences of all tests achieving P-values <0.05 were considered to be statistically significant. Variables that achieved statistical significance on univariate analysis were entered into multiple logistic regression analysis to identify significant risk factors. Potential risk factors associated with SR included the following variables: gender, age, body mass index (BMI), HBV DNA, HBsAg, HBeAg, HBeAb, HBcAb, ALT, TCHO, TG, HDL-C, HDL-C/C, LDL-C, VLDL-C, APO-A1, APO-B, APO-A1/B, LP(α) and NEFA.

Results

Clinical characteristics of HBeAg-positive CHB patients receiving PEG-IFN-α treatment

Among 119 HBeAg-positive CHB patients, 65 patients were treated with PEG-IFN-α monotherapy and 54 patients were treated with PEG-IFN-α add-on NAs. Baseline characteristics of patients are shown in Table 1. SR group had significantly lower mean HBsAg level (3.9 ±0.6 versus 4.1 ±0.5 log₁₀ IU/ml; P=0.029), higher mean ALT level (270 ±203 versus 176 ±105 U/l; P=0.003), lower mean HBeAg level (2.7 ±0.6 versus 3.0 ±0.3 log₁₀ S/CO; P<0.001) and lower mean anti-HBe level (29.3 ±22.5 versus 47.5 ±20.8 S/CO; P<0.001) than NR group. HBV DNA level was decreased in SR group compared with NR group although there were no statistical differences. No significant differences were observed in other baseline parameters between the two groups.

Table 1

Clinical characteristics of the study cohort

	SR (n=53)	NR (n=66)	P-value
Baseline characteristics
Gender, n M/n F	35/18	53/13	0.112
Age, years	27 ±5	28 ±5	0.286
Log₁₀ HBV DNA, IU/ml	7.1 ±1.0	7.4 ±0.8	0.085
Log₁₀ HBsAg, IU/ml	3.9 ±0.6	4.1 ±0.5	0.029
Log₁₀ HBeAg, S/CO	2.7 ±0.6	3.0 ±0.3	<0.001
Anti-HBe, S/CO	29.3 ±22.5	47.5 ±20.8	<0.001
Anti-HBc, S/CO	11.5 ±5.5	11.2 ±2.5	0.733
ALT, U/l	270 ±203	176 ±105	0.003
Treatment
PEG-IFN-α monotherapy, n (%)	38 (31.9)	27 (22.7)	–
PEG-IFN-α add-on NAs, n (%)	15 (12.6)	39 (32.8)	–

Data are mean ±sd unless otherwise indicated. Bold font indicates statistical significance (P<0.05). ALT, alanine aminotransferase; anti-HBc, hepatitis B core antibody; anti-HBe, hepatitis B e antibody; HBeAg, hepatitis B e antigen; HBsAg, hepatitis B surface antigen; NAs, nucleoside/nucleotide analogues; NR, non-response; PEG-IFN-α, pegylated interferon-alfa; SR, sustained response.

Correlation between serum lipid levels and therapeutic response

To identify whether there was a correlation between serum lipids and the anti-HBV therapeutic response, we compared the levels of all the clinical serum lipid indicators (TCHO, TG, HDL-C, HDL-C/C, LDL-C, VLDL-C, APO-A1, APO-B, APO-A1/B, LP[α] and NEFA) between SR and NR groups. We found that the baseline serum level of TCHO (4.62 ±0.85 versus 4.19 ±0.71 mmol/l; P=0.004), LDL-C (2.79 ±0.77 versus 2.45 ±0.63 mmol/l; P=0.011) and APO-B (0.88 ±0.22 versus 0.79 ±0.20 mmol/l; P=0.029) were higher in the NR group than those in the SR group (Figures 1A-C). While the baseline serum level of HDL-C/C was lower in NR group compared to SR group (0.31 ±0.09 versus 0.35 ±0.09, P=0.039; Figure 1D). No significant differences were observed in other clinical baseline serum lipid levels between two groups (data not shown). Furthermore, we analysed the dynamic variations of serum TCHO, LDL-C, HDL-C/C and APO-B levels throughout the course of treatment. We found that only baseline serum levels had significant differences between SR and NR groups (Figure 2). Besides, serum TCHO and LDL-C levels tended to decline throughout the course of treatment.

Figure 1

The baseline serum lipid levels correlated with the therapeutic response to PEG-IFN-α in HBeAg-positive CHB patients

Figure 2

The dynamic variations of serum lipid levels throughout the course of treatment

Correlation between serum lipid levels and serum markers of HBV replication before treatment

Correlation analyses showed a significant positive correlation between TCHO and log₁₀ HBsAg (r=0.247; P=0.009) as well as anti-HBe (r=0.255; P=0.008), and a significant negative correlation between TCHO and anti-HBc (r=-0.237; P=0.019; Table 2). LDL-C showed positive correlation with log₁₀ HBsAg (r=0.207; P=0.031) and was negatively correlated with anti-HBc (r=-0.307; P=0.002; Table 2). HDL-C/C showed positive correlation with anti-HBc (r=0.245; P=0.016) and APO-B showed negative correlation with anti-HBc (r=-0.368; P=0.001; Table 2).

Table 2

Correlation of serum lipids with HBV markers at baseline in HBeAg-positive CHB patients

	Log₁₀ HBV DNA		Log₁₀ HBsAg		Log₁₀ HBeAg		Anti-HBe		Anti-HBc
	r value	P-value	r value	P-value	r value	P-value	r value	P-value	r value	P-value
TCHO, mmol/l	0.120	0.203	0.247	0.009	0.152	0.107	0.255	0.008	-0.237	0.019
TG, mmol/l	-0.131	0.162	-0.093	0.333	-0.020	0.833	0.011	0.908	-0.162	0.110
HDL-C, mmol/l	-0.056	0.554	-0.007	0.943	-0.012	0.898	0.088	0.373	0.108	0.292
HDL-C/C	-0.144	0.129	-0.175	0.069	-0.138	0.146	-0.103	0.298	0.245	0.016
LDL-C, mmol/l	0.136	0.150	0.207	0.031	0.125	0.189	0.178	0.069	-0.307	0.002
VLDL-C, mmol/l	-0.130	0.167	-0.134	0.164	0.006	0.946	-0.005	0.956	-0.167	0.102
APO-A1, g/l	-0.085	0.369	0.009	0.924	0.016	0.871	0.026	0.791	-0.079	0.442
APO-B, g/l	0.265	0.106	0.186	0.053	0.174	0.067	0.186	0.058	-0.368	0.001
APO-A1/B	-0.149	0.116	-0.125	0.195	-0.120	0.208	-0.115	0.241	0.238	0.019
LP(α), mg/l	0.036	0.723	0.039	0.702	-0.122	0.224	-0.240	0.020	0.007	0.947
NEFA, μEq/l	0.057	0.569	0.132	0.195	-0.152	0.130	-0.157	0.132	-0.202	0.056

Bold font indicates statistical significance (P<0.05). Anti-HBc, hepatitis B core antibody; anti-HBe, hepatitis B e antibody; APO-A1, apolipoprotein A1; APO-A1/B, the ratio of APO-A1 to APO-B; APO-B, apolipoprotein B; CHB, chronic hepatitis B; HBeAg, hepatitis B e antigen; HBsAg, hepatitis B surface antigen; HDL-C, high-density lipoprotein cholesterol; HDL-C/C, the ratio of HDL-C to TCHO; LDL-C, low-density lipoprotein cholesterol; LP(α), lipoprotein a; NEFA, non-esterified fatty acid; TCHO, total cholesterol; TG, triglyceride; VLDL-C, very low-density lipoprotein cholesterol.

To investigate the influence of the baseline serum TCHO on chronic HBV infection in greater detail, according to the clinical reference range of serum TCHO (3.6∼5.69), the 119 HBeAg-positive CHB patients were divided into three groups: low TCHO group (baseline serum TCHO levels were <3.6 mmol/l); middle TCHO group (baseline serum TCHO levels were from 3.6 to 5.69 mmol/l); high TCHO group (baseline serum TCHO levels were >5.69 mmol/l). Then, the dynamic variations of six clinical serological and virological indices (HBsAg, HBeAg, anti-HBe, anti-HBc, HBV DNA and ALT) in different levels of serum TCHO throughout the course of treatment were analysed. We found that CHB patients with the high baseline TCHO levels exhibited higher HBV DNA, HBsAg, HBeAg and HBeAb levels during early treatment periods (weeks 0, 4, 12 and 24) than those with the low TCHO levels (Figures 3A–D). However, no correlation was found between decreases in two indices (anti-HBc and ALT) compared with the respective controls (Figures 3E–F), both during the course of treatment (0–48 weeks) and at 24 weeks post-treatment (week 72). The above analysis indicated that CHB patients harbouring high baseline serum TCHO levels exhibited a relatively poor therapeutic response to PEG-IFN-α.

Figure 3

The dynamic variations of clinical serological and virological indices in different levels of baseline serum TCHO throughout the course of PEG-IFN-α treatment

Baseline serum TCHO may serve as a risk factor for therapeutic response to PEG-IFN-α among HBeAg-positive CHB patients

Logistic regression analysis was used to identify risk factors of therapeutic response. Univariate analysis identified eight parameters that influenced the SR. The baseline serum HBsAg, HBeAg, anti-HBe, TCHO, LDL-C and APO-B were suggested as detrimental to SR achievement for CHB patients treated with PEG-IFN-α (OR=2.37, P=0.036; OR=6.50, P=0.001; OR=1.04, P<0.001; OR=2.02, P<0.005; OR=2.02, P=0.014; OR=7.24, P=0.033, respectively; Table 3). Conversely, we found two protective effects of baseline serum ALT and HDL-C/C to achieve SR (OR=0.996, P=0.004; OR=0.013, P=0.042, respectively; Table 3). Multivariate analysis that included the above variables identified three parameters that influenced the SR. The baseline serum HBeAg and TCHO were still suggested as detrimental to SR achievement (OR=19.15, P=0.022; OR=4.94, P=0.047, respectively) and ALT was still suggested as protective to SR achievement (OR=0.994, P=0.004; Table 3). These results suggested that baseline serum TCHO, as the only clinical serum lipid indicator that was correlated with a detrimental outcome in the multivariate analysis, can be used as an effective risk factor for identifying the non-response to PEG-IFN-α therapy before treatment for HBV infection.

Table 3

Logistic regression analysis to identify risk factors of PEG-IFN-α treatment response in HBeAg-positive CHB patients

Baseline characteristics	Univariate analysis		Multivariate analysis
Baseline characteristics	OR^a (95% CI)	P-value	OR (95% CI)	P-value
Male	2.10 (0.91, 4.82)	0.081	–	–
Age	1.04 (0.97, 1.12)	0.285	–	–
Log₁₀ HBV DNA, IU/ml	1.53 (0.94, 2.50)	0.091	–	–
Log₁₀ HBsAg, IU/ml	2.37 (1.06, 5.31)	0.036	0.44 (0.15, 1.29)	0.135
Log₁₀ HBeAg, S/CO	6.50 (2.22, 19.03)	0.001	19.15 (1.52, 241.21)	0.022
Anti-HBe, S/CO	1.04 (1.02, 1.06)	<0.001	1.01 (0.97, 1.04)	0.768
Anti-HBc, S/CO	0.73 (0.89, 1.08)	0.983	–	–
ALT, U/l	0.996 (0.993, 0.999)	0.004	0.994 (0.991, 0.998)	0.004
BMI, kg/m²	1.07 (0.92, 1.23)	0.381	–	–
TCHO, mmol/l	2.02 (1.23, 3.30)	0.005	4.94 (1.03, 23.79)	0.047
TG, mmol/l	1.95 (0.71, 5.37)	0.198	–	–
HDL-C, mmol/l	0.89 (0.34, 2.27)	0.803	–	–
HDL-C/C	0.013 (0.00, 0.85)	0.042	0.01 (0.00, 42.08)	0.249
LDL-C, mmol/l	2.02 (1.15, 3.52)	0.014	0.57 (0.07, 4.40)	0.587
VLDL-C, mmol/l	4.29 (0.47, 39.14)	0.197	–	–
APO-A1, g/l	1.39 (0.35, 5.48)	0.637	–	–
APO-B, g/l	7.24 (1.17, 44.88)	0.033	0.13 (0.00, 12.72)	0.379
APO-A1/B	0.64 (0.34, 1.19)	0.157	–	–
LP(α), mg/l	1.00 (0.998, 1.003)	0.630	–	–
NEFA, μEq/l	1.00 (0.998, 1.001)	0.546	–	–

Bold font indicates statistical significance (P<0.05). ^aOdds ratio (OR) >1 indicates a detrimental association with response to treatment. OR <1 indicates a protective association with response to treatment. ALT, alanine aminotransferase; anti-HBc, hepatitis B core antibody; anti-HBe, hepatitis B e antibody; APO-A1, apolipoprotein A1; APO-A1/B, the ratio of APO-A1 to APO-B; APO-B, apolipoprotein B; BMI, body mass index; CHB, chronic hepatitis B; HBeAg, hepatitis B e antigen; HBsAg, hepatitis B surface antigen; HDL-C, high-density lipoprotein cholesterol; HDL-C/C, the ratio of HDL-C to TCHO; LDL-C, low-density lipoprotein cholesterol; LP(α), lipoprotein α; NEFA, non-esterified fatty acid; PEG-IFN-α, pegylated interferon-alfa; TCHO, total cholesterol; TG, triglyceride; VLDL-C, very low-density lipoprotein cholesterol.

Discussion

Currently, clinical studies suggested that several factors were associated with PEG-IFN-α therapeutic efficacy in CHB patients [26]. However, these factors were gained several weeks after treatment began. The ideal factors would be assessed before treatment to identify CHB patients that were not likely to respond to PEG-IFN-α therapy. We previously reported that polymorphisms of CYP27B1 were associated with PEG-IFN-α therapeutic efficacy in HBeAg-positive patients [27] and baseline serum HBV large surface protein (HBV-LP) level can be used for predicting virological response to PEG-IFN-α in CHB patients [28]. Nevertheless, these indicators have not been commonly detected in clinic.

Previous reports found that serum lipids played a key role in determining the outcome of HCV infection [29]. However, the sustained role of serum lipids in regulating HBV infection during PEG-IFN-α treatment is largely unknown. The present study demonstrated that a majority of NR CHB patients harbour high baseline serum TCHO levels compared to SR CHB patients. Besides, the dynamic analysis of serum TCHO levels throughout the course of treatment showed that only baseline TCHO levels had significant differences between SR and NR groups. We also examined the correlation between TCHO and HBV markers. The results discovered that baseline serum TCHO showed positive correlation with HBsAg, as well as anti-HBe. Moreover, CHB patients with the high baseline TCHO levels exhibited higher HBV DNA, HBsAg, HBeAg and HBeAb levels during early treatment periods (weeks 0, 4, 12 and 24) than those with the low TCHO levels. These results revealed that CHB patients harbouring high baseline serum TCHO levels exhibited a relatively poor therapeutic response to PEG-IFN-α. On the other hand, the univariate regression analysis suggested that low ALT concentrations, high HBsAg concentrations and high HBeAg concentrations at baseline associated with poor response to PEG-IFN-α, which are consistent with previous reports [30–32]. In addition, these data also recommended that high baseline HBV DNA and anti-HBe concentrations were concerned with NR to PEG-IFN-α. Interestingly, baseline serum TCHO was the only clinical serum lipid indicator that was statistically significantly correlated with a detrimental outcome to PEG-IFN-α therapy in the multivariate analysis.

The above analysis indicated that high serum TCHO levels were associated with failure to achieve durable HBeAg seroconversion induced by PEG-IFN-α therapy. To investigate whether serum TCHO levels were associated with spontaneous HBeAg seroconversion, we compared 81 patients with HBeAg-negative chronic HBV infection (inactive carriers) and 50 patients with HBeAg-positive chronic HBV infection (immune tolerant carriers). Clinical characteristics of patients were shown in Additional file 1. We found that the TCHO levels in the immune tolerant carriers group were significantly higher than those in the inactive carriers group (4.92 ±0.88 versus 4.56 ±0.73 mmol/l; P=0.011; Additional file 2). These data indicated that lower TCHO levels were associated with a state that is more likely to lead to spontaneous HBeAg seroconversion.

Considered together, our results suggest that the baseline TCHO can be used as a clinical risk factor that can be easily detected before clinical PEG-IFN-α treatment. However, the reason why serum cholesterol is concerned with therapeutic efficacy of PEG-IFN-α in CHB patients is unclear.

Previous studies have offered some evidence: bile acids increase HBV gene expression which counteracts the antiviral effect of IFN-α [33] and inhibits the induction of proteins involved in the antiviral activity of IFN, such as 2,5-oligoadenylate synthetase (OAS) [34]. It is noteworthy that bile acids derive from cholesterol, namely the cholesterol 7α-hydroxylase promotes bile acid synthesis by increasing the conversion of cholesterol to bile acids [35]. Therefore, we suppose that serum cholesterol affects the efficacy of IFN-α treatment through influencing the bile acid metabolism in CHB patients, which may need further validation.

In this study, a certain proportion of CHB patients were assigned to receive PEG-IFN-α add-on NAs. To investigate whether the treatment regimen affects the level of TCHO, we compared the serum TCHO levels from CHB patients treated with either PEG-IFN-α monotherapy or PEG-IFN-α/NA add-on at the indicated time points since PEG-IFN-α treatment. However, no significant differences were detected at any time point since PEG-IFN-α treatment (Additional file 3).

In conclusion, our findings identify a previously unrecognized role of baseline serum TCHO in HBeAg-positive CHB patients during PEG-IFN-α treatment. The high baseline serum TCHO levels can provide an explanation for the poor therapeutic effect of PEG-IFN-α treatment in some CHB patients. Moreover, these findings present an auxiliary clinical indicator for evaluating the efficacy of PEG-IFN-α therapy in CHB patients.

Footnotes

The authors declare no competing interests.

Additional file 1: A table showing clinical characteristics of patients with chronic HBV infection can be found at

Additional file 2: A figure showing the serum TCHO levels correlated with spontaneous HBeAg seroconversion can be found at

Additional file 3: A figure showing the level of TCHO from CHB patients treated with PEG-IFN-α monotherapy (n=65) or PEG-IFN-α/NA add-on (n=54) at the indicated time points since PEG-IFN-α treatment can be found at

Acknowledgements

This work was supported by the National Natural Science Foundation of China (grant number 81572067); and the Joint Funds for the Innovation of Science and Technology of Fujian Province (grant number 2016Y9020).

References

Schweitzer

, Horn

, Mikolajczyk

R.T.

, Krause

, Ott

J.J.

Estimations of worldwide prevalence of chronic hepatitis B virus infection: a systematic review of data published between 1965 and 2013. Lancet 2015; 386: 1546–1555

McMahon

B.J.

The natural history of chronic hepatitis B virus infection. Hepatology 2009; 49: S45–S55

Tang

L.S.Y.

, Covert

, Wilson

, Kottilil

Chronic hepatitis B infection: a review. JAMA 2018; 319: 1802–1813

Marcellin

, Lau

G.K.

, Bonino

Peginterferon alfa-2a alone, lamivudine alone, and the two in combination in patients with HBeAg-negative chronic hepatitis B. N Engl J Med 2004; 351: 1206–1217

Bonino

, Marcellin

, Lau

G.K.

Predicting response to peginterferon alpha-2a, lamivudine and the two combined for HBeAg-negative chronic hepatitis B. Gut 2007; 56: 699–705

Terrault

N.A.

, Bzowej

N.H.

, Chang

K.M.

AASLD guidelines for treatment of chronic hepatitis B. Hepatology 2016; 63: 261–283

Janssen

H.L.A.

, van Zonneveld

, Senturk

Pegylated interferon alfa-2b alone or in combination with lamivudine for HBeAg-positive chronic hepatitis B: a randomised trial. Lancet 2005; 365: 123–129

Buster

E.H.

, Flink

H.J.

, Cakaloglu

Sustained HBeAg and HBsAg loss after long-term follow-up of HBeAg-positive patients treated with peginterferon alpha-2b. Gastroenterology 2008; 135: 459–467

Yuen

M-F

, Lai

C-L

Treatment of chronic hepatitis B. Lancet Infect Dis 2001; 1: 232–241

10.

Lau

G.K.

, Piratvisuth

, Luo

K.X.

Peginterferon alfa-2a, lamivudine, and the combination for HBeAg-positive chronic hepatitis B. N Engl J Med 2005; 352: 2682–2695

11.

Yang

, Yan

, He

Expression of hepatitis B virus proteins in transgenic mice alters lipid metabolism and induces oxidative stress in the liver. J Hepatol 2008; 48: 12–19

12.

Shi

Y.X.

, Huang

C.J.

, Yang

Z.G.

Impact of hepatitis B virus infection on hepatic metabolic signaling pathway. World J Gastroenterol 2016; 22: 8161–8167

13.

Wang

, Wu

, Hu

Intracellular hepatitis B virus increases hepatic cholesterol deposition in alcoholic fatty liver via hepatitis B core protein. J Lipid Res 2018; 59: 58–68

14.

Y.J.

, Zhu

, Liang

, Yin

W.G.

, Xiao

J.H.

Hepatitis B virus induces expression of cholesterol metabolism-related genes via TLR2 in HepG2 cells. World J Gastroenterol 2013; 19: 2262–2269

15.

Kang

S.K.

, Chung

T.W.

, Lee

J.Y.

, Lee

Y.C.

, Morton

R.E.

, Kim

C.H.

The hepatitis B virus X protein inhibits secretion of apolipoprotein B by enhancing the expression of N-acetylglucosaminyltransferase III. J Biol Chem 2004; 279: 28106–28112

16.

Kim

, Kim

K.H.

, Kim

H.H.

, Cheong

Hepatitis B virus X protein induces lipogenic transcription factor SREBP1 and fatty acid synthase through the activation of nuclear receptor LXRalpha. Biochem J 2008; 416: 219–230

17.

Bremer

C.M.

, Bung

, Kott

, Hardt

, Glebe

Hepatitis B virus infection is dependent on cholesterol in the viral envelope. Cell Microbiol 2009; 11: 249–260

18.

Chu

C.M.

, Lin

D.Y.

, Liaw

Y.F.

Does increased body mass index with hepatic steatosis contribute to seroclearance of hepatitis B virus (HBV) surface antigen in chronic HBV infection?

Int J Obes (Lond) 2007; 31: 871–875

19.

Funk

, Mhamdi

, Hohenberg

Duck hepatitis B virus requires cholesterol for endosomal escape during virus entry. J Virol 2008; 82: 10532–10542

20.

Ramcharran

, Wahed

A.S.

, Conjeevaram

H.S.

Associations between serum lipids and hepatitis C antiviral treatment efficacy. Hepatology 2010; 52: 854–863

21.

Pollock

, Nichita

N.B.

, Böhmer

, Radulescu

, Dwek

R.A.

, Zitzmann

Polyunsaturated liposomes are antiviral against hepatitis B and C viruses and HIV by decreasing cholesterol levels in infected cells. Proc Natl Acad Sci U S A 2010; 107: 17176–17181

22.

Akuta

, Suzuki

, Kawamura

Predictive factors of early and sustained responses to peginterferon plus ribavirin combination therapy in Japanese patients infected with hepatitis C virus genotype 1b: amino acid substitutions in the core region and low-density lipoprotein cholesterol levels. J Hepatol 2007; 46: 403–410

23.

Gopal

, Johnson

T.C.

, Gopal

Correlation between beta-lipoprotein levels and outcome of hepatitis C treatment. Hepatology 2006; 44: 335–340

24.

Harrison

S.A.

, Rossaro

, Hu

K.Q.

Serum cholesterol and statin use predict virological response to peginterferon and ribavirin therapy. Hepatology 2010; 52: 864–874

25.

Lampertico

, Agarwal

, Berg

EASL 2017 Clinical Practice Guidelines on the management of hepatitis B virus infection. J Hepatol 2017; 67: 370–398

26.

Sarin

S.K.

, Kumar

, Lau

G.K.

Asian-Pacific clinical practice guidelines on the management of hepatitis B: a 2015 update. Hepatol Int 2016; 10: 1–98

27.

, Zeng

, Wu

, Lin

, Ou

Polymorphisms of CYP27B1 are associated with IFN efficacy in HBeAg-positive patients. J Clin Lab Anal 2018; 32: e22367

28.

Liu

, Wu

, Shang

Prediction value of serum HBV large surface protein in different phases of HBV infection and virological response of chronic hepatitis B patients. Clin Chim Acta 2018; 481: 12–19

29.

Felmlee

D.J.

, Hafirassou

M.L.

, Lefevre

, Baumert

T.F.

, Schuster

Hepatitis C virus, cholesterol and lipoproteins–impact for the viral life cycle and pathogenesis of liver disease. Viruses 2013; 5: 1292–1324

30.

Sonneveld

M.J.

, Hansen

B.E.

, Piratvisuth

Response-guided peginterferon therapy in hepatitis B e antigen-positive chronic hepatitis B using serum hepatitis B surface antigen levels. Hepatology 2013; 58: 872–880

31.

Fried

M.W.

, Piratvisuth

, Lau

G.K.

HBeAg and hepatitis B virus DNA as outcome predictors during therapy with peginterferon alfa-2a for HBeAg-positive chronic hepatitis B. Hepatology 2008; 47: 428–434

32.

Buster

E.H.

, Hansen

B.E.

, Lau

G.K.

Factors that predict response of patients with hepatitis B e antigen-positive chronic hepatitis B to peginterferon-alfa. Gastroenterology 2009; 137: 2002–2009

33.

Kim

H.Y.

, Cho

H.K.

, Choi

Y.H.

, Lee

K.S.

, Cheong

Bile acids increase hepatitis B virus gene expression and inhibit interferon-alpha activity. FEBS J 2010; 277: 2791–2802

34.

Podevin

, Rosmorduc

, Conti

, Calmus

, Meier

P.J.

, Poupon

Bile acids modulate the interferon signalling pathway. Hepatology 1999; 29: 1840–1847

35.

Oehler

, Volz

, Bhadra

O.D.

Binding of hepatitis B virus to its cellular receptor alters the expression profile of genes of bile acid metabolism. Hepatology 2014; 60: 1483–1493

Association of Serum Total Cholesterol with Pegylated Interferon-α Treatment in HBeAg-Positive Chronic Hepatitis B Patients

Abstract

Background

Methods

Results

Introduction

Methods

Patient characteristics

Measurement of clinical indicators

Statistical analyses

Results

Clinical characteristics of HBeAg-positive CHB patients receiving PEG-IFN-α treatment

Correlation between serum lipid levels and therapeutic response

Correlation between serum lipid levels and serum markers of HBV replication before treatment

Baseline serum TCHO may serve as a risk factor for therapeutic response to PEG-IFN-α among HBeAg-positive CHB patients

Discussion

Footnotes

Acknowledgements

References